The Molecular Tumor Board: Best Practices for Managing Primary and Acquired EGFR TKI Resistance

Do you know that primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) occurs in approximately 20% to 30% of patients with EGFR-mutated non-small cell lung cancer (NSCLC), and acquired resistance is inevitable? Credit available for this activity expires: 5/23/2023 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/974097?src=mkm_podcast_addon_974097